A blog by Ronny Allan

Fat‑Soluble Vitamins in Neuroendocrine Tumours (NETs): Why Deficiency Happens and Who Is Most at Risk

Fat‑Soluble Vitamins in Neuroendocrine Tumours (NETs): Why Deficiency Happens and Who Is Most at Risk


This blog provides general educational information only. It does not offer medical advice, diagnosis, or treatment. Patients should always consult their clinical team for personalised guidance.

 

Introduction: What Are Fat‑Soluble Vitamins?

Fat‑soluble vitamins — A, D, E and K — are nutrients that can only be absorbed when dietary fat is digested properly. They rely on bile acids, pancreatic enzymes, and a healthy small intestine (especially the jejunum and ileum) to form tiny droplets called micelles, which carry these vitamins across the gut wall. Unlike water‑soluble vitamins, they are stored in the liver and fatty tissues, so deficiencies develop slowly and often silently. Because neuroendocrine tumours — and their treatments — can disrupt fat digestion at several points, NET patients are more vulnerable to deficiencies in these vitamins than the general population.

 

Why NET Patients Are at Higher Risk of Fat‑Soluble Vitamin Deficiency (Ranked by Risk Profile)

These categories are not rigid, but they help clarify the relative risk profiles across NET subtypes.

1. Pancreatic NETs with Exocrine Insufficiency — Highest Risk

Pancreatic NETs can impair the pancreas’s ability to produce digestive enzymes. Without adequate lipase and bile‑stimulated enzyme activity, fat digestion becomes inefficient — and fat‑soluble vitamins (A, D, E, K) depend entirely on this process. Patients with exocrine insufficiency, steatorrhoea, or those requiring PERT sit at the top of the risk spectrum.

2. Small Intestine NETs (Jejunum + Ileum) and Small Bowel Surgery — High Risk

Small intestine NETs — including both jejunal and ileal NETs — sit firmly in the high‑risk category.

  • The jejunum is the primary site of nutrient absorption.
  • The ileum is essential for bile acid recycling and coordinated fat uptake.

Tumours or resections in either region reduce the surface area and transit time needed for ADEK absorption. Vitamin D and Vitamin K are particularly vulnerable because Vitamin D relies heavily on intact small‑bowel fat handling, while Vitamin K depends on bile acid recycling in the terminal ileum.

This is also where bile acid malabsorption becomes important. Without a gallbladder, bile is no longer stored or released in a concentrated surge, and somatostatin analogues further reduce bile flow. If the terminal ileum has been resected or damaged, bile acids cannot be recycled. The combined effect reduces the bile acid pool needed to form micelles, meaning that fat‑soluble vitamin absorption can fall even when pancreatic function is normal.

Common procedures such as ileal resection, segmental small bowel resection, or right hemicolectomy further increase this risk. Even without surgery, small intestine NETs can disrupt mucosal function and bile acid handling.

Special Case: Metastatic Appendiceal NET with Right Hemicolectomy — Moderate Risk

Although localised appendiceal NETs are usually low‑risk, metastatic appendiceal NETs — particularly those treated with a right hemicolectomy — behave more like small intestine NETs. Loss of the terminal ileum and ileocaecal valve increases the risk of bile acid malabsorption, rapid transit, and fat‑soluble vitamin deficiency. If somatostatin analogues are also used, the risk rises further.  For localised, non‑metastatic appendiceal neuroendocrine tumours, the direct risk of malabsorption is inherently low. Because the tumour is confined to the appendix and does not cause systemic hormone secretion or bowel‑obstructing nodal disease, the digestive tract remains fully functional. When these tumours are removed with curative intent and the patient is discharged back to primary care, there is no evidence‑based reason to expect fat‑soluble vitamin deficiency. Risk only increases if surgery extends into the terminal ileum or if somatostatin analogues are introduced later for unrelated disease progression.

3. Chronic Diarrhoea — Moderate to High Risk (Predominantly Midgut)

Chronic diarrhoea is one of the strongest functional drivers of ADEK deficiency. It is most commonly seen in midgut NETs, where:

However, diarrhoea can also occur in:

  • pancreatic NETs with exocrine insufficiency
  • any NET patient on long‑term SSAs

Risk level varies with severity and frequency, but is generally moderate to high.

4. Duodenal NETs — Moderate Risk

Duodenal NETs sit in a moderate‑risk category. The duodenum is a key site for mixing bile and pancreatic enzymes, so tumours here — or surgery involving this region — can subtly impair fat digestion. Gastrinomas may add further risk through acid‑related malabsorption. If somatostatin analogues are also used, the risk increases. While not as high‑risk as pancreatic or small intestine NETs, duodenal NETs remain part of the malabsorption spectrum.

5. Long‑Term Somatostatin Analogue (SSA) Therapy — Moderate Risk

SSAs reduce:

  • pancreatic enzyme secretion
  • bile flow
  • gallbladder contraction (if present)
  • intestinal motility

All of these are required for normal fat digestion. On their own, SSAs usually cause mild‑to‑moderate impairment of fat absorption. However, when combined with small‑bowel disease, small‑bowel surgery, gallbladder removal, or pancreatic insufficiency, the effect becomes clinically significant.

Boundary Statement

“These categories are not rigid, but they help clarify the relative risk profiles. Pancreatic NETs with exocrine insufficiency sit at the highest end of the spectrum, followed by small intestine NETs and surgery. Chronic diarrhoea — most commonly seen in midgut NETs — adds further risk, and long‑term somatostatin analogue therapy contributes additional strain on fat absorption. Understanding these boundaries helps explain why fat‑soluble vitamin testing is so relevant in NET care.”

Why Testing Matters

Fat‑soluble vitamin deficiency is often silent until advanced. Symptoms overlap with:

  • SSA side effects
  • ageing
  • general cancer fatigue
  • post‑surgical changes

This is why periodic monitoring is recommended in several NET care pathways.

Examples of Subtle Symptoms

  • Vitamin A → night vision issues
  • Vitamin D → bone pain, low mood
  • Vitamin E → neuropathy‑like symptoms
  • Vitamin K → easy bruising

Key Takeaways

  • ADEK vitamins rely on bile acids, pancreatic enzymes and healthy small‑bowel absorption.
  • Small intestine NETs (jejunum + ileum) are high‑risk because they disrupt the main absorption zones.
  • Pancreatic NETs with exocrine insufficiency are the highest‑risk group.
  • SSAs add a meaningful layer of malabsorption, especially without a gallbladder.
  • Chronic diarrhoea — especially midgut‑related — accelerates losses.
  • Testing is important but can be complex.

 

References Used

  1. ESMO – Reducing deficiencies of fat-soluble vitamins, vitamin B12, and vitamin B3 in patients with neuroendocrine tumors treated with somatostatin analogues – L.D. de Hosson, S. Bunskoek, J. Stelwagen, B. Sijtema, S. Huitema, M. van Faassen, G.H. de Bock, D.J.A. de Groot, M.J.E. Campmans-Kuijpers, I.P. Kema, E.G.E. de Vries, A.M.E. Walenkamp, Volume 4, 2025, 100032, ISSN 3050-4619, https://doi.org/10.1016/j.esmorc.2025.100032. (https://www.sciencedirect.com/science/article/pii/S3050461925000310)


See individual fat soluble vitamins here:


Vitamin A – click here

Vitamin D  click here

Vitamin E  click here

Vitamin K  click here


For some, the same issues can have an effect on the following water soluble vitamins

Vitamin B3 – click here

Vitamin B9 click here

Vitamin B12 – click here

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.


Click here and answer all questions to join my private Facebook group



 


Discover more from Ronny Allan - Living with Neuroendocrine Cancer

Subscribe to get the latest posts sent to your email.

By Ronny Allan

Ronny Allan is a 3 x award-winning accredited patient leader advocating internationally for Neuroendocrine Cancer and all other cancer patients generally. Check out his Social Media accounts including Facebook, BlueSky, WhatsApp, Instagram and and X.

I love comments - feel free!

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Posts

Discover more from Ronny Allan - Living with Neuroendocrine Cancer

Subscribe now to keep reading and get access to the full archive.

Continue reading

Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.